Reaction
Glioblastoma reporting signals
As of the last recalculation, Glioblastoma appears in 1,651 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is TEMOZOLOMIDE (PRR 192.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Temozolomide | 269 | 192.1 | 194.6 |
| Bevacizumab | 275 | 33.4 | 33.5 |
| Selinexor | 20 | 29.5 | 29.5 |
| Lacosamide | 51 | 17.8 | 17.8 |
| Levetiracetam | 166 | 17.3 | 17.3 |
| Levetiracetam In Sodium Chloride | 76 | 12.9 | 12.9 |
| Levetiracetam Oral | 76 | 12.9 | 12.9 |
| Levetiracetam Injection | 76 | 12.9 | 12.9 |
| Extended Phenytoin Sodium | 13 | 9.9 | 9.9 |
| Regorafenib | 8 | 8.7 | 8.7 |
| Trametinib | 15 | 7.9 | 7.9 |
| Dabrafenib | 13 | 7.8 | 7.8 |
| Osimertinib | 17 | 6.7 | 6.7 |
| Imatinib | 9 | 6.5 | 6.5 |
| Romiplostim | 7 | 5.9 | 5.9 |
| Brivaracetam | 4 | 5.6 | 5.6 |
| Lapatinib | 6 | 4.9 | 4.9 |
| Olaparib | 8 | 4.8 | 4.8 |
| Eltrombopag Olamine | 8 | 4.4 | 4.4 |
| Benralizumab | 5 | 3.2 | 3.2 |
| Somatropin | 16 | 2.8 | 2.8 |